Abstract Library

#4666 Merkel cell neuroendocrine carcinoma of the skin: High response rates to short course palliative radiotherapy – Typical clinical scenarios

Introduction: Merkel cell carcinomas (MCC) are a rare, aggressive skin neuroendocrine carcinomas, with peak incidence in the elderly. MCC often presents as a firm, red/purple painless nodule with a short history of increasing size. Surgery is considered the 1st line treatment but elderly patients, in particular, have comorbidities which may preclude radical surgery requiring reconstruction. In advanced MCC, immunotherapy (IO) is 1st line systemic treatment. Chemotherapy is used 2nd line or if contraindications for IO but can be challenging in an elderly population. There may be an emerging role for PRRT due to the presence of somatostatin receptors on MCC. Radiotherapy (RT) can be used for non-surgical candidates, or those with unresectable or metastatic disease. Adjuvant post-operative irradiation (PORT) may provide additional benefit in risk reduction and improves local control.

Conference:

Presenting Author:

Authors: Saunders E, Sizer B, Collins J, Skelly R, Srinivasan G,

Keywords: Merkel cell, skin, radiotherapy,

#4594 RNA splicing as a key regulatory player with translational potential in pulmonary neuroendocrine neoplasms (lungNETs)

Introduction: Neuroendocrine tumours (NETs) are a diverse group of neoplasms arising from neuroendocrine cells. Within this group, lung neuroendocrine tumours (LungNETs) represent one of the most frequent subtypes of NETs. LungNETs are classified by grade, according to their proliferative index and aggressiveness. Among them, typical carcinoids (G1) and atypical carcinoids (G2) are the lowest grade subtypes. While these tumours are less aggressive, they remain underexplored compared to higher-grade subtypes, highlighting the need for molecular studies to improve clinical approaches. In this context, previous studies have shown that abnormalities in the splicing machinery are frequent in tumour pathologies and also occur in LungNETs.

Conference:

Presenting Author:

Authors: Gutiérrez Camacho L, Ruiz-Palacios D, García Vioque V, González-Pérez C, Moreno Montilla M,

Keywords: splicing, neuroendocrine tumour, Lung NET, typical carcinoid, atypical carcinoid,

#4593 Excellent response to Ac-225 DOTATATE therapy in a patient with small cell lung cancer

Introduction: Peptide receptor radionuclide therapy (PRRT) is a validated treatment for patients with NETs overexpressing somatostatin receptors (SSTR). IHC analysis indicates that up to 50% of small cell lung cancer (SCLC) tumours are SSTR2 positive and thus can be targeted by SSR imaging and PRRT. Therapy with α-emitting radionuclides, such as Ac225, may offer several advantages over β-emitters by having higher energy transfer and more effective cancer cell death.

Conference:

Presenting Author: Tuncel M

Authors: Tuncel M, Türkan C, Eryılmaz Y, Pala A, Kılıçkap S,

Keywords: Ac-225 DOTATATE, Small Cell lung cancer, PET, somatostatin receptor, PRRT,

#4559 Exploring the interplay between RNA methylation and splicing dysregulation in neuroendocrine tumours

Introduction: Post-transcriptional modifications play crucial roles in regulating gene expression and cellular function. While recent findings indicate that alternative splicing dysregulation plays a key role in tumorigenic properties of neuroendocrine tumours (NETs), the role of other RNA processing mechanisms, such as N6-methyladenosine (m6A) — being the most common RNA methylation — remains largely unexplored in NETs.

Conference:

Presenting Author:

Authors: Ruiz-Palacios D, Gutiérrez Camacho L, García Vioque V, Moreno Montilla M, Blázquez-Encinas R,

Keywords: RNA methylation, splicing, neuroendocrine tumour, lung NET, pan NET,

#4206 Specific spliceosomic landscapes reveal a possible link between RNA processing and panNETs behaviour

Introduction: Pancreatic Neuroendocrine Tumors (PanNETs) are characterized by a low number of mutations. Despite genomics, transcriptomics and epigenomics studies have helped to understand the molecular features of PanNETs, there is still a vast unexplored ground for better comprehension of this disease. In this context, we have previously documented that RNA splicing is dysregulated in these tumors, which unveils new avenues to discover potential biomarkers and therapeutic targets. However, clinical and molecular implications of this dysregulation are still very poorly understood.

Conference:

Presenting Author: Pedraza-Arévalo S

Authors: Pedraza-Arévalo S, Blázquez-Encinas R, García-Vioque V, Moreno-Montilla M, Ruiz-Palacios D,

Keywords: pancreatic neuroendocrine tumor, splicing, RNA, grade, metastasis,